These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 8488856)

  • 1. Pathobiology of restenosis after angioplasty.
    Haudenschild CC
    Am J Med; 1993 Apr; 94(4A):40S-44S. PubMed ID: 8488856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of restenosis.
    Haudenschild CC
    Z Kardiol; 1989; 78 Suppl 3():28-34. PubMed ID: 2530710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of restenosis. A correlation of clinical observations with cellular responses.
    Haudenschild CC
    Z Kardiol; 1990; 79 Suppl 3():17-22. PubMed ID: 2099039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Restenosis and arterial remodelling after coronary angioplasty].
    Jørgensen B; Forfang K
    Tidsskr Nor Laegeforen; 1996 Aug; 116(20):2460-3. PubMed ID: 8928109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioplasty.
    Matsuura R; Isaka N; Imanaka-Yoshida K; Yoshida T; Sakakura T; Nakano T
    J Pathol; 1996 Nov; 180(3):311-6. PubMed ID: 8958811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathophysiology of restenosis following percutaneous transluminal coronary angioplasty].
    Holm AM; Haunsø S; Hansen PR
    Ugeskr Laeger; 1998 Feb; 160(9):1302-6. PubMed ID: 9495077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: serial coronary angiography and intravascular ultrasound studies].
    Yoshinuma M
    J Cardiol; 1999 Feb; 33(2):81-8. PubMed ID: 10087476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging.
    Wyttenbach R; Gallino A; Alerci M; Mahler F; Cozzi L; Di Valentino M; Badimon JJ; Fuster V; Corti R
    Circulation; 2004 Aug; 110(9):1156-61. PubMed ID: 15326071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanisms and prevention of restenosis after coronary angioplasty].
    Drechsel S; Bertel O; Lafont A
    Schweiz Med Wochenschr; 1998 Mar; 128(13):497-507. PubMed ID: 9583101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Restenosis after percutaneous transluminal coronary angioplasty and its prevention].
    Przewłocka-Kosmala M; Kosmala W
    Przegl Lek; 1999; 56(10):671-5. PubMed ID: 10695384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Standards in interventional therapy of coronary artery disease].
    Rutsch W; Gliech V; Dübel HP; Borges A; Theres H; Laule M; Baumann G
    Herz; 2002 Sep; 27(6):481-501. PubMed ID: 12378393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing restenosis after angioplasty: a multistage approach.
    Zargham R
    Clin Sci (Lond); 2008 Feb; 114(4):257-64. PubMed ID: 18194134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of late lumen loss after antiproliferative percutaneous coronary intervention using beta-irradiation in a porcine model of restenosis.
    Deiner C; Loddenkemper C; Rauch U; Rosenthal P; Pauschinger M; Schwimmbeck PL; Schultheiss HP; Pels K
    Cardiovasc Revasc Med; 2007; 8(2):94-8. PubMed ID: 17574167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty.
    Inoue T; Sakai Y; Morooka S; Hayashi T; Takayanagi K; Takabatake Y
    J Am Coll Cardiol; 1996 Nov; 28(5):1127-33. PubMed ID: 8890805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway.
    Yang YB; Yang YX; Su B; Tang YL; Zhu BY; Hu ZW; Li GY; Li YJ; Liao DF
    Eur J Pharmacol; 2007 Sep; 570(1-3):125-34. PubMed ID: 17628533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Restenosis: physiopathology, treatments and prevention].
    Lafont A; Durand E; Rahal S; de Oliveira M; Guérin Y; Fernandez F; Desnos M; Guérot C
    Ann Cardiol Angeiol (Paris); 1995 Sep; 44(7):349-53. PubMed ID: 8561439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the risk of restenosis after peripheral angioplasty: critical reflections].
    Cristol R
    J Mal Vasc; 1993; 18(2):96-8. PubMed ID: 8350020
    [No Abstract]   [Full Text] [Related]  

  • 18. Restenosis: stalwart foe in peripheral vasculature.
    D'Agincourt L
    Diagn Imaging (San Franc); 1992 Nov; 14(11):114-21. PubMed ID: 10147849
    [No Abstract]   [Full Text] [Related]  

  • 19. [Percutaneous transluminal angioplasty].
    Madsen B; Grandt M
    Ugeskr Laeger; 1983 May; 145(22):1667-70. PubMed ID: 6224332
    [No Abstract]   [Full Text] [Related]  

  • 20. Transluminal angioplasty in peripheral vascular disease.
    Maggisano R; Jones BA; Saibil E
    Can J Surg; 1985 Sep; 28(5):387-8. PubMed ID: 3161605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.